Gumokimab is the eighth successfully approved drug developed independently by Akeso (with six already approved for market), and it is also the third non-oncology innovative drug, following ebronucimab ...

We have previously demonstrated that interleukin-17A (IL-17) producing T helper 17 cells are significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A promotes MM ...

Multiple drugs that target the IL-17 pathway are being investigated in clinical trials for various inflammatory diseases, and the first therapeutic antibody that inhibits IL-17 was approved for ...